Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy

Inclusion criteria

• HIV-1 infected patient
• Initial TT ARV started above (or equal to) 150 / mm3 LT CD4, and 18 months prior to inclusion in the study
• Ongoing antiretroviral therapy combining tenofovir + emtricitabine + a 3rd agent (IP / r, IP, NNRTI, II, Inhibitors) with at least one undetectable viral load (CV <50 copies / mL) after introduction of the latter treatment.
• Patient in virological success: CV <50 copies / mL for at least 12 months, including visit to selection.
• Absence of previous therapeutic failure: no viral load ≥ 200 copies / mL (after 6 months of treatment) (Except in the case of a justified therapeutic interruption: travel, stock-out ...) and of obtaining success Virologic after introduction of treatment, without concept of genotypic resistance known to the ARVs used.
• Cellular DNA-HIV <2.7 log copies / 106 PBMC
• Zenith RNA-HIV <150,000 copies / ml (excluding viral load values during primary infection if it is documented)
• No genotypic resistance to currently used and known ARVs
• Patient who has given written informed consent
• Affiliate or beneficiary of a social security scheme
• Patient followed on an outpatient basis, age ≥ 18 years.

Exclusion criteria

• Non-compliant patient
• Subject is pregnant, or lactating, or of childbearing potential and without contraception
• Active opportunistic infections
• Major overweight (BMI ≥ 40)
• Severe renal pathology (creatinine clearance < 30ml/min)
• Cirrhosis or severe liver failure (factor V < 50%)
• Prognosis threatened within 6 months
• Circumstances that may impair judgment or understanding of the information given to the patient
• Malabsorption syndromes
• The following laboratory criteria:

• Serum ASAT,ALAT > 5 x upper limit of normal (ULN)
• Thrombocytopenia with platelet count < 50.000/ml
• Anemia with hemoglobin < 8g/dl
• Polynuclear neutrophil count < 500/mm3